India
· Delayed Price · Currency is INR Suven Life Sciences Statistics
Total Valuation
Suven Life Sciences has a market cap or net worth of INR 33.35 billion. The enterprise value is 30.96 billion.
| Market Cap | 33.35B |
| Enterprise Value | 30.96B |
Important Dates
The next estimated earnings date is Friday, October 25, 2024.
| Earnings Date | Oct 25, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Suven Life Sciences has 218.07 million shares outstanding. The number of shares has increased by 10.71% in one year.
| Shares Outstanding | 218.07M |
| Shares Change (YoY) | +10.71% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 2.27% |
| Owned by Institutions (%) | 13.85% |
| Float | 58.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 374.00 |
| PB Ratio | 12.35 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -28.40 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,048.65 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | -26.37% |
| Revenue Per Employee | 631,319 |
| Profits Per Employee | -7.73M |
| Employee Count | 141 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +119.13% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +119.13% |
| 50-Day Moving Average | 137.74 |
| 200-Day Moving Average | 109.85 |
| Relative Strength Index (RSI) | 60.45 |
| Average Volume (20 Days) | 64,522 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Suven Life Sciences had revenue of INR 89.02 million and -1.09 billion in losses. Loss per share was -5.01.
| Revenue | 89.02M |
| Gross Profit | 80.77M |
| Operating Income | -1.37B |
| Pretax Income | -1.10B |
| Net Income | -1.09B |
| EBITDA | -1.31B |
| EBIT | -1.37B |
| Loss Per Share | -5.01 |
Balance Sheet
The company has 2.40 billion in cash and 7.10 million in debt, giving a net cash position of 2.39 billion or 10.97 per share.
| Cash & Cash Equivalents | 2.40B |
| Total Debt | 7.10M |
| Net Cash | 2.39B |
| Net Cash Per Share | 10.97 |
| Equity (Book Value) | 2.70B |
| Book Value Per Share | 12.38 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 90.74% |
| Operating Margin | -1,534.99% |
| Pretax Margin | -1,236.05% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Suven Life Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.71% |
| Shareholder Yield | -10.71% |
| Earnings Yield | -3.28% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on March 23, 2007. It was a forward split with a ratio of 4.
| Last Split Date | Mar 23, 2007 |
| Split Type | Forward |
| Split Ratio | 4 |